Association of classical risk factors and coronary artery disease in type 2 diabetic patients submitted to coronary angiography

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Bittencourt, Célia ^a   Piveta, Valdecira M ^a   Oliveira, Carolina S ^a   Crispim, Felipe ^a   Meira, Deyse ^a   Saddi Rosa, Pedro ^a   Giuffrida, Fernando M ^b   Reis, André F ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b CEDEBA   (Brazil)

Author keywords

Coronary artery disease; Risk factors; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; FRAMINGHAM RISK SCORE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84899099517     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-46     Document Type: Article

References (33)

1. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M, N Engl J Med 1998 339 229 234 10.1056/NEJM199807233390404 9673301
2. Diabetes and cardiovascular disease. The Framingham study. Kannel WB, McGee DL, JAMA 2035-2038 1979 241
3. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. Huxley R, Barzi F, Woodward M, BMJ 2006 332 73 78 10.1136/bmj.38678.389583.7C 16371403
4. Cardiovascular disease and diabetes. Schaan BD, Reis AF, Arq Bras Endocrinol Metabol 2007 51 151 152 10.1590/S0004-27302007000200002 17505620
5. Type 2 diabetes and cardiovascular risk factors. Sharma MD, Farmer JA, Garber A, Curr Med Res Opin 2011 27 Suppl 3 1 5
6. Is hyperglycemia a cardiovascular risk factor? Pistrosch F, Natali A, Hanefeld M, Diabetes Care 2011 34 Suppl 2 128 31 21525443
7. Cardiovascular disease in diabetes mellitus: classical and non-classical risk factors. Siqueira AFA, De Almeida-Pititto B, Ferreira SRG, Arq Bras Endocrinol Metabol 2007 51 257 267 10.1590/S0004-27302007000200014 17505632
8. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ, American Heart Association, American Diabetes Association, Diabetes Care 2007 30 162 172 10.2337/dc07-9917 17192355
9. Effect of a multifactorial intervention on mortality in type 2 diabetes. Gaede P, Lund-Andersen H, Parving H-H, Pedersen O, N Engl J Med 2008 358 580 591 10.1056/NEJMoa0706245 18256393
10. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Stamler J, Vaccaro O, Neaton JD, Wentworth D, Diabetes Care 1993 16 434 444 10.2337/diacare.16.2.434 8432214
11. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, De Boer M-J, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc J-J, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, et al. European Heart Journal 2007 28 1 88 136 17220161
12. ADIPOQ and adiponectin: the common ground of hyperglycemia and coronary artery disease? Oliveira CSV, Giuffrida FMA, Crispim F, Saddi-Rosa P, Reis AF, Arq Bras Endocrinol Metabol 2011 55 446 454 10.1590/S0004-27302011000700003 22147092
13. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Ann Intern Med 1999 130 461 470 10.7326/0003-4819-130-6-199903160-00002 10075613
14. Standards of medical care in diabetes - 2013. American Diabetes Association, Diabetes Care 2013 36 Suppl 1 11 66 23264422
15. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, Wilson PW, JAMA 2003 290 891 897 10.1001/jama.290.7.891 12928465
16. Use and abuse of HOMA modeling. Wallace TM, Levy JC, Matthews DR, Diabetes Care 2004 27 1487 1495 10.2337/diacare.27.6.1487 15161807
17. Prediction of coronary heart disease using risk factor categories. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB, Circulation 1837-1847 1998 97
18. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Circulation 2002 106 3143 3421 12485966
19. Hemoglobin A1C in non-diabetic patients: an independent predictor of coronary artery disease and its severity. Ashraf H, Boroumand MA, Amirzadegan A, Talesh SA, Davoodi G, Diabetes Res Clin Pract 2013 102 225 232 10.1016/j.diabres.2013.10.011 24176244
20. 10-year follow-up of intensive glucose control in type 2 diabetes. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW, N Engl J Med 2008 359 1577 1589 10.1056/NEJMoa0806470 18784090
21. Effects of intensive glucose lowering in type 2 diabetes. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT, Action to Control Cardiovascular Risk in Diabetes Study Group, N Engl J Med 2008 358 2545 2559 18539917
22. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F, ADVANCE Collaborative Group, N Engl J Med 2008 358 2560 2572 18539916
23. Glucose control and vascular complications in veterans with type 2 diabetes. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, VADT Investigators, N Engl J Med 2009 360 129 139 10.1056/NEJMoa0808431 19092145
24. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS, American Diabetes Association, American College of Cardiology Foundation, American Heart Association, Diabetes Care 2009 32 1 187 192 10.2337/dc08-9026 19092168
25. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Sattar N, Diabetologia 2013 56 686 695 10.1007/s00125-012-2817-5 23354123
26. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C, Cholesterol Treatment Trialists' (CTT) Collaborators, Lancet 2012 380 581 590 22607822
27. Is insulin resistance atherogenic? Possible mechanisms. Defronzo RA, Atheroscler Suppl 2006 7 11 15
28. Insulin resistance and cardiovascular disease. Ginsberg HN, Journal of Clinical Investigation 2000 106 453 458 10.1172/JCI10762 10953019
29. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study Group, BMJ 1998 317 703 713 10.1136/bmj.317.7160. 703 9732337
30. Intensive lifestyle intervention in type 2 diabetes. Wing RR, Reboussin D, Lewis CE, Look AHEAD Research Group, N Engl J Med 2013 369 2358 2359 24328474
31. Body weight and mortality in type 2 diabetes: weighing up the evidence. Logue J, Sattar N, Diabetes Metab 2013 39 287 288 10.1016/j.diabet.2013.06.002 23928206
32. Association of weight status with mortality in adults with incident diabetes. Carnethon MR, De Chavez PJD, Biggs ML, Lewis CE, Pankow JS, Bertoni AG, Golden SH, Liu K, Mukamal KJ, Campbell-Jenkins B, Dyer AR, JAMA 2012 308 581 590 22871870
33. Hypoadiponectinemia-cause or consequence of human "insulin resistance"? Cook JR, Semple RK, J Clin Endocrinol Metab 2010 95 1544 1554 10.1210/jc.2009-2286 20164291